SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
Aldostefano Porcari(Azienda Sanitaria Universitaria Integrata di Trieste), Marianna Fontana(Amyloidosis Foundation), Aviva Petrie(Eastman Dental Hospital), Alberto Cipriani(Azienda Ospedale - Università Padova), Simone Longhi(Azienda USL di Bologna), Beatrice Musumeci(Sapienza University of Rome), Michele Emdin(Scuola Superiore Sant'Anna), Gianfranco Sinagra(Società Italiana di Cardiologia), Philip N. Hawkins(The Royal Free Hospital), Cristina Chimenti(Policlinico Umberto I), Valentina Allegro(University of Trieste), Christian Nitsche(Medical University of Vienna), Mattia Zampieri(Azienda Ospedaliero-Universitaria Careggi), Rishi Patel(Texas Tech University), Marco Metra(Vita-Salute San Raffaele University), Scott D. Solomon(Brigham and Women's Hospital), Adam Ioannou(The Royal Free Hospital), Marcus A. Urey(University of California San Diego), Daniela Tomasoni(University of Brescia), Carol Whelan(The Royal Free Hospital), Giulio Sinigiani(University of Padua), Ahmad Masri(Oregon Health & Science University), Yousuf Razvi(The Royal Free Hospital), Marco Canepa(Ospedale Policlinico San Martino), Muhammad U. Rauf(The Royal Free Hospital), Marco Merlo(Ospedale Policlinico San Martino), Christina Kronberger(Medical University of Vienna), Francesco Cappelli(National Institute of Optics), R Badr-Eslam(Medical University of Vienna), Luca Bordignon(University of Trieste), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Matteo Serenelli(Cardiovascular Institute of the South)
Cited by 137
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2022|2.6k